Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY2025. Opioid and heroin addiction legislation, naloxone access and awareness.
2025 · 1st Quarter (Jan 1 - Mar 31)
EMERGENT BIOSOLUTIONS
Filed by THE NICKLES GROUP, LLC.
Open official filingSource-reported fields
Filing overview
- Type
- 1st Quarter - Report
- Posted
- Apr 18, 2025
- Income
- $40,000.00
- Expenses
- Not reported
- Registrant
- THE NICKLES GROUP, LLC
- Client
- EMERGENT BIOSOLUTIONS
- Filing UUID
- 4bb152cc-4ec6-41d4-84ce-7a4ef996aaf0
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Reauthorization of Pandemic and All-Hazards Preparedness and Advancing Innovation Act, Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY25 and FY26, Opioid crisis legislation, naloxone access and awareness, FY2026 NDAA provisions related to biological and chemical defense and access to naloxone, H.R. 1968, the Full-Year Continuing Appropriations and Extensions Act, 2025
Literal federal measure citations: H.R. 1968
National Defense Authorization Act for FY2025, provisions related to biological and chemical defense and access to naloxone.
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.